<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01277419</url>
  </required_header>
  <id_info>
    <org_study_id>GESPIC</org_study_id>
    <nct_id>NCT01277419</nct_id>
  </id_info>
  <brief_title>German Spondyloarthritis Inception Cohort</brief_title>
  <acronym>GESPIC</acronym>
  <official_title>German Spondyloarthritis Inception Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research (BMBF): 2000-2007 and 2010-2019</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centocor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Berlin Institute of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <brief_summary>
    <textblock>
      The German Spondyloarthritis Inception cohort (GESPIC) was started 2000 as a prospective,
      longitudinal, multicentre, nationwide study in Germany on patients with early SpA including
      ankylosing spondylitis (AS, also known as radiographic axial spondyloarthritis) and
      non-radiographic axial SpA. The objectives of GESPIC are to learn about the course of SpA
      during the very early stage of the disease, to appropriately assess the outcome including
      radiographic progression of patients after several years of follow-up, to identify outcome
      predictors, to assess quality of life, function, and costs (direct and indirect costs).
      GESPIC has been recently expanded to recruit patients with other forms of SpA / conditions
      associated with SpA: acute anterior uveitis, Crohn's disease as well as with psoriasis /
      axial psoriatic arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2000</start_date>
  <completion_date type="Anticipated">July 2030</completion_date>
  <primary_completion_date type="Anticipated">July 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Non-radiographic Axial Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Ankylosing spondylitis</arm_group_label>
    <description>Ankylosing spondylitis according to the modified New York criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-radiographic axial spondyloarthritis</arm_group_label>
    <description>Patients with clinical characteristics of axial SpA but not fulfilling the modified New York criteria for which radiographic sacroiliitis is essential.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Juvenile spondyloarthritis</arm_group_label>
    <description>Patients with juvenile spondyloarthritis (juvenile ankylosing spondylitis, juvenile non-AS-spondyloarthritis).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crohn's disease</arm_group_label>
    <description>Crohn's disease with duration of symptoms ≤5 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute anterior uveitis</arm_group_label>
    <description>Patients with acute anterior uveitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Axial psoriatic arthritis</arm_group_label>
    <description>Patients with psoriatic arthritis with axial involvement (sacroiliac joints and/or spine)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients included in GESPIC are required to have a definite clinical diagnosis of axial SpA
        / juvenile SpA (currently only adult patients with radiographic axial SpA = ankylosing
        spondylitis - AS are recruited) or a definite diagnosis of Crohn's disease or a definite
        diagnosis of acute anterior uveitis or a definite diagnosis of psoriatic arthritis with
        axial involvement.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Main inclusion Criteria:

          -  Patients with definite diagnosis of axial spondyloarthritis or juvenile
             spondyloarthritis.

          -  Patients with definite diagnosis of Crohn's disease.

          -  Patients with definite diagnosis of acute anterior uveitis.

          -  Patients with definite diagnosis of psoriatic arthritis with axial involvement.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joachim Sieper, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Rudwaleit, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Denis Poddubnyy, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Denis Poddubnyy, Prof. Dr.</last_name>
    <phone>+4930450514582</phone>
    <email>denis.poddubnyy@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annegret Langdon</last_name>
      <email>annegret.langdon@charite.de</email>
    </contact>
    <investigator>
      <last_name>Valeria Rios Rodriguez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mikhail Protopopov, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabian Proft, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Judith Rademacher, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://rheuma.charite.de</url>
    <description>Coordinating study center: Department of rheumatology, Charité - Campus Benjamin Franklin</description>
  </link>
  <results_reference>
    <citation>Rudwaleit M, Haibel H, Baraliakos X, Listing J, Märker-Hermann E, Zeidler H, Braun J, Sieper J. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum. 2009 Mar;60(3):717-27. doi: 10.1002/art.24483.</citation>
    <PMID>19248087</PMID>
  </results_reference>
  <results_reference>
    <citation>Poddubnyy DA, Rudwaleit M, Listing J, Braun J, Sieper J. Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis. 2010 Jul;69(7):1338-41. doi: 10.1136/ard.2009.120139. Epub 2010 May 24.</citation>
    <PMID>20498207</PMID>
  </results_reference>
  <results_reference>
    <citation>Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Märker-Hermann E, Zeidler H, Braun J, Sieper J. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011 Aug;70(8):1369-74. doi: 10.1136/ard.2010.145995. Epub 2011 May 27.</citation>
    <PMID>21622969</PMID>
  </results_reference>
  <results_reference>
    <citation>Poddubnyy DA, Märker-Hermann E, Kaluza-Schilling W, Zeidler H, Braun J, Listing J, Sieper J, Rudwaleit M. Relation of HLA-B27, tumor necrosis factor-α promoter gene polymorphisms, and T cell cytokine production in ankylosing spondylitis -- a comprehensive genotype-phenotype analysis from an observational cohort. J Rheumatol. 2011 Nov;38(11):2436-41. doi: 10.3899/jrheum.110130. Epub 2011 Sep 1.</citation>
    <PMID>21885496</PMID>
  </results_reference>
  <results_reference>
    <citation>Heiland GR, Appel H, Poddubnyy D, Zwerina J, Hueber A, Haibel H, Baraliakos X, Listing J, Rudwaleit M, Schett G, Sieper J. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis. 2012 Apr;71(4):572-4. doi: 10.1136/annrheumdis-2011-200216. Epub 2011 Dec 20.</citation>
    <PMID>22186710</PMID>
  </results_reference>
  <results_reference>
    <citation>Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Märker-Hermann E, Zeidler H, Braun J, Sieper J. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis. 2012 Oct;71(10):1616-22. doi: 10.1136/annrheumdis-2011-201252. Epub 2012 Mar 29.</citation>
    <PMID>22459541</PMID>
  </results_reference>
  <results_reference>
    <citation>Poddubnyy D, Haibel H, Listing J, Märker-Hermann E, Zeidler H, Braun J, Sieper J, Rudwaleit M. Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort (GESPIC). Ann Rheum Dis. 2013 Aug;72(8):1430-2. doi: 10.1136/annrheumdis-2012-203148. Epub 2013 Apr 26.</citation>
    <PMID>23625981</PMID>
  </results_reference>
  <results_reference>
    <citation>Poddubnyy D, Conrad K, Haibel H, Syrbe U, Appel H, Braun J, Rudwaleit M, Sieper J. Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis. Ann Rheum Dis. 2014 Dec;73(12):2137-43. doi: 10.1136/annrheumdis-2013-203824. Epub 2013 Aug 16.</citation>
    <PMID>23956246</PMID>
  </results_reference>
  <results_reference>
    <citation>Turina MC, Sieper J, Yeremenko N, Conrad K, Haibel H, Rudwaleit M, Baeten D, Poddubnyy D. Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. Ann Rheum Dis. 2014 Sep;73(9):1746-8. doi: 10.1136/annrheumdis-2014-205506. Epub 2014 May 20.</citation>
    <PMID>24845387</PMID>
  </results_reference>
  <results_reference>
    <citation>Syrbe U, Callhoff J, Conrad K, Poddubnyy D, Haibel H, Junker S, Frommer KW, Müller-Ladner U, Neumann E, Sieper J. Serum adipokine levels in patients with ankylosing spondylitis and their relationship to clinical parameters and radiographic spinal progression. Arthritis Rheumatol. 2015 Mar;67(3):678-85. doi: 10.1002/art.38968.</citation>
    <PMID>25417763</PMID>
  </results_reference>
  <results_reference>
    <citation>Poddubnyy D, Haibel H, Braun J, Rudwaleit M, Sieper J. Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort. Arthritis Rheumatol. 2015 Sep;67(9):2369-75. doi: 10.1002/art.39225.</citation>
    <PMID>26017497</PMID>
  </results_reference>
  <results_reference>
    <citation>Poddubnyy D, Protopopov M, Haibel H, Braun J, Rudwaleit M, Sieper J. High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort. Ann Rheum Dis. 2016 Dec;75(12):2114-2118. doi: 10.1136/annrheumdis-2016-209209. Epub 2016 Apr 28.</citation>
    <PMID>27125522</PMID>
  </results_reference>
  <results_reference>
    <citation>Protopopov M, Sieper J, Haibel H, Listing J, Rudwaleit M, Poddubnyy D. Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Res Ther. 2017 Oct 24;19(1):240. doi: 10.1186/s13075-017-1453-3.</citation>
    <PMID>29065931</PMID>
  </results_reference>
  <results_reference>
    <citation>Poddubnyy D, Listing J, Haibel H, Knüppel S, Rudwaleit M, Sieper J. Functional relevance of radiographic spinal progression in axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort. Rheumatology (Oxford). 2018 Apr 1;57(4):703-711. doi: 10.1093/rheumatology/kex475.</citation>
    <PMID>29373733</PMID>
  </results_reference>
  <results_reference>
    <citation>Boel A, Molto A, van der Heijde D, Ciurea A, Dougados M, Gensler LS, Santos MJ, De Miguel E, Poddubnyy D, Rudwaleit M, van Tubergen A, van Gaalen FA, Ramiro S. Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts. Ann Rheum Dis. 2019 Nov;78(11):1545-1549. doi: 10.1136/annrheumdis-2019-215707. Epub 2019 Jul 30.</citation>
    <PMID>31362994</PMID>
  </results_reference>
  <results_reference>
    <citation>Llop M, Rios Rodriguez V, Redeker I, Sieper J, Haibel H, Rudwaleit M, Poddubnyy D. Incorporation of the anteroposterior lumbar radiographs in the modified Stoke Ankylosing Spondylitis Spine Score improves detection of radiographic spinal progression in axial spondyloarthritis. Arthritis Res Ther. 2019 May 24;21(1):126. doi: 10.1186/s13075-019-1913-z.</citation>
    <PMID>31126334</PMID>
  </results_reference>
  <results_reference>
    <citation>de Winter JJ, Blijdorp IC, de Jong HM, Sauter J, Schmidt AH, van Gaalen FA, van der Heijde D, Poddubnyy D, Yeremenko NG, van de Sande MG, Baeten DL. HLA-C*07 in axial spondyloarthritis: data from the German Spondyloarthritis Inception Cohort and the Spondyloarthritis Caught Early cohort. Genes Immun. 2019 Nov;20(8):671-677. doi: 10.1038/s41435-019-0061-4. Epub 2019 Feb 26. Erratum in: Genes Immun. 2019 May 9;:.</citation>
    <PMID>30809016</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>January 14, 2011</study_first_submitted>
  <study_first_submitted_qc>January 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2011</study_first_posted>
  <last_update_submitted>September 9, 2019</last_update_submitted>
  <last_update_submitted_qc>September 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Denis Poddubnyy</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

